<SEC-DOCUMENT>0001140361-26-029841.txt : 20260728
<SEC-HEADER>0001140361-26-029841.hdr.sgml : 20260728
<ACCEPTANCE-DATETIME>20260728082037
ACCESSION NUMBER:		0001140361-26-029841
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260724
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260728
DATE AS OF CHANGE:		20260728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34180
		FILM NUMBER:		261207585

	BUSINESS ADDRESS:	
		STREET 1:		50 MILK STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		50 MILK STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20078901_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:lab="http://standardbio.com/20260724" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_861ec0aef1d84f5ba7c6c697e0ef6b68" contextRef="c20260724to20260724" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_176632a8287a461e813df44714114ebe" contextRef="c20260724to20260724">0001162194</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="lab-20260724.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20260724to20260724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-07-24</xbrli:startDate><xbrli:endDate>2026-07-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div><span style="font-size: 14pt;"> </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_ee836757957043af84fe802cb3246a11" contextRef="c20260724to20260724">8-K</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to Section 13 or 15(d) of the</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Securities Exchange Act of 1934</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_f9821ea81345473e929c41317545c072" contextRef="c20260724to20260724" format="ixt:date-monthname-day-year-en">July 24, 2026</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a23463cd153545f8a9ba78d5839e701f" contextRef="c20260724to20260724">Standard BioTools Inc.</ix:nonNumeric></span><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div>
        <div style="text-align: center;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_2682c261781c404b8aeafa6dfeaf8286" contextRef="c20260724to20260724" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_4ed55bcd72a34823868315fdbc8cdb4c" contextRef="c20260724to20260724">001-34180</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_c1dfbe6c65be4b67b6dbb34b6907dfb7" contextRef="c20260724to20260724">77-0513190</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_9bc1eab1ad834bf0af813a4f4ac9273c" contextRef="c20260724to20260724">50 Milk Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_6ba03140fac54ffe93bfb829328e54e4" contextRef="c20260724to20260724">10th Floor</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_d28c2f40cb624077b7b54f0f2ab27cbd" contextRef="c20260724to20260724">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_b397fe831fae48b2914ce97992ee4bbb" contextRef="c20260724to20260724" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_d6be81257b2d445aa71db67f9856f0c3" contextRef="c20260724to20260724">02109</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices) (Zip Code)</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_cc7ae89db63d4e85b67baeb7cb4dd950" contextRef="c20260724to20260724">650</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_63c465d4a012458196326116d406dad9" contextRef="c20260724to20260724">266-6000</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Former Name or Former Address, if Changed Since Last Report)</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
        (<span style="font-family: 'Times New Roman'; font-style: italic;">see</span> General Instruction A.2. below):</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_98ee54a9da5543dda089b25dd5261292" contextRef="c20260724to20260724" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_9d1ad37624e446ae84145258f187e7f5" contextRef="c20260724to20260724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_e6b5c3a5ca634811b3b6808a5c397b27" contextRef="c20260724to20260724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_593185b7f7e7427ca3fb46c7749e8540" contextRef="c20260724to20260724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 41%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title of each class</div>
            </td>

    <td style="width: 17.75%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Trading Symbol(s)</div>
            </td>

    <td style="width: 40.56%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 41%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_f1f4ee78351a4f1b93aae1ab15595f01" contextRef="c20260724to20260724">Common stock, par value $0.001 per share</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 17.75%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_42b45e70351444d989005ffa573a643d" contextRef="c20260724to20260724">LAB</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 40.56%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_6a609d36738e4ec6861e49adb760ed04" contextRef="c20260724to20260724" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2
        of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_1a9a2b7eef0d44a3b18f77481bee5c6d" contextRef="c20260724to20260724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>

      <div style="font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Termination, Waiver and Release Agreement</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">On July 24, 2026, Standard BioTools Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Termination, Waiver and Release Agreement (the &#8220;Termination Agreement&#8221;)
        with Illumina, Inc., a Delaware corporation (&#8220;Illumina&#8221;). Pursuant to the terms of the Termination Agreement, the Company has received a payment of approximately $30 million in cash from Illumina in exchange for the waiver and release of certain
        earnout and royalty payment obligations and the termination of certain other agreements described below.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Stock Purchase Agreement, dated June 22, 2025, by and between the Company and Illumina (the &#8220;Illumina Stock Purchase Agreement&#8221;), Illumina, among other
        things, agreed to make an earnout payment based upon net revenue generated from SomaScan assay services or any other SOMAmer-based assay services and sales of SOMAmer-based array kits and SOMAmer-based next-generation sequencing library preparation
        kits in fiscal year 2026 (such earnout payment, the &#8220;2026 Illumina Earnout&#8221;).</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the closing of the transactions contemplated by the Illumina Stock Purchase Agreement, on January 30, 2026 the Company and Illumina entered into (i) a
        royalty agreement, pursuant to which the Company was entitled to a specified royalty stream on net revenues generated from sales of SOMAmer-based next-generation sequencing library preparation kits, (ii) a license agreement, pursuant to which
        Illumina provided a specified license to the Company for the intellectual property relating to Single SOMAmers for potential development and commercialization of Single SOMAmer reagents for use in singleplex affinity assays and (iii) a royalty
        agreement, pursuant to which the Company was entitled to a specified royalty stream on net revenues generated from sales of Single SOMAmers (clauses (i), (ii) and (iii), collectively, the &#8220;Royalty and License Agreements&#8221;).</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Termination Agreement, the Company agreed with Illumina to waive its rights to the 2026 Illumina Earnout and to terminate the Royalty and License
        Agreements.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Termination
        Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Share and Asset Purchase Agreement</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">On July 28, 2026, the Company entered into a Share and Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Multiplex Bio Inc., a Delaware corporation (&#8220;Multiplex
        Bio&#8221;). Pursuant to the Purchase Agreement, on the terms and subject to the conditions set forth therein, Multiplex Bio will acquire the mass cytometry business (the &#8220;Business&#8221;) of the Company (collectively, the &#8220;Transaction&#8221;).</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Under the Purchase Agreement, the aggregate purchase price for the Transaction is $5 million, on a cash-free and debt-free basis and subject to customary adjustments
        contemplated by the Purchase Agreement (as so adjusted, the &#8220;Closing Payment&#8221;). The Closing Payment is payable entirely through the issuance to the Company by Multiplex Bio, at the consummation of the Transaction (the &#8220;Closing&#8221;), of a promissory
        note in a principal amount equal to the Closing Payment, bearing interest at a rate of 6% per annum and maturing on the fifth anniversary of the Closing. The Company will not receive cash consideration at the Closing. Pursuant to the Purchase
        Agreement, the Company may receive additional consideration of $5 million if Multiplex Bio consummates a qualifying sale transaction for consideration in excess of a specified dollar threshold within ten years of the Closing. Under the Purchase
        Agreement, Multiplex Bio is required to use reasonable best efforts to obtain a senior secured working capital loan facility, available to it after the Closing on terms reasonably satisfactory to the Company, and if Multiplex Bio is unable to
        obtain such financing prior to the Closing despite using such efforts, the Company must provide Multiplex Bio a working capital loan at the Closing in an amount of up to $10 million.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Purchase Agreement contemplates that the parties will enter into certain other ancillary agreements as of the Closing, including a transition services agreement,
        pursuant to which the Company will provide specified services to Multiplex Bio following the Closing in connection with Multiplex Bio&#8217;s operation of the Business.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Purchase Agreement contains customary representations, warranties and covenants by the parties, and the consummation of the Transaction is subject to customary
        closing conditions. Receipt of approval of the Company&#8217;s stockholders for the Transaction, as well as consummation of the Company&#8217;s pending merger with Treeline Biosciences, Inc., are also conditions to the Closing.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Purchase Agreement contains a customary non-solicitation restriction on the Company&#8217;s ability to solicit or facilitate alternative proposals to acquire the Business,
        subject to a customary fiduciary out that permits the Company&#8217;s board of directors (the &#8220;Company Board&#8221;), prior to approval of the Transaction by Company stockholders, to change its recommendation or terminate the Purchase Agreement in order to
        accept an unsolicited competing proposal to acquire the Business that is more favorable to stockholders from a financial point of view, subject to Multiplex Bio&#8217;s notice and matching rights, if the Company Board determines in good faith (after
        consultation with its outside financial and legal advisors) that failing to do so would be inconsistent with its fiduciary duties.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Purchase Agreement also provides for customary termination rights for both parties, including, among other things, the ability of each of the Company or Multiplex Bio
        to terminate the Purchase Agreement if the Transaction has not been consummated on or before June 30, 2027, subject to up to two automatic three-month extensions under certain specified circumstances. Upon termination of the Purchase Agreement
        under specified circumstances, the Company will be required to make a payment to Multiplex Bio equal to $1 million in cash (the &#8220;Termination Fee&#8221;). The Company will be required to reimburse Multiplex Bio&#8217;s reasonable out-of-pocket fees in
        connection with the Transaction in an amount up to $125,000 if the Transaction is not consummated prior to December 31, 2026, and up to an additional $125,000 if the Transaction is not consummated prior to March 31, 2027, with the amount of any
        such reimbursement to be credited against any payment of the Termination Fee.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 7.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Regulation FD Disclosure.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">On July 28, 2026, the Company issued a press release, announcing the transactions described in this Current Report on Form 8-K. A copy of the press release is furnished
        as Exhibit 99.1 hereto and is incorporated herein by reference.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The information set forth in this Item 7.01 and in the attached Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of
        1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others,
        statements regarding the disposition of the Mass Cytometry business; the expected timing of the disposition of the Mass Cytometry business; the Treeline transaction; the expected timing of the closing of the Treeline transaction; the potential
        benefits of the Treeline transaction; the prospective performance and outlook of the combined company&#8217;s business, performance and opportunities&#894; as well as any assumptions underlying any of the foregoing. The words &#8220;advance,&#8221; &#8220;build,&#8221; &#8220;lead,&#8221;
        &#8220;may,&#8221; &#8220;will,&#8221; &#8220;continue,&#8221; &#8220;commitment,&#8221; &#8220;expect,&#8221; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially
        different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the risk that the sale of the Mass Cytometry
        business may not be completed in a timely manner or at all; (ii) the ability to obtain the requisite approval for the sale of the Mass Cytometry business from stockholders of Standard BioTools; (iii) the possibility that any or all of the various
        conditions to the consummation of the sale of the Mass Cytometry business may not be satisfied or waived; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement relating to the sale
        of the Mass Cytometry business; (v) the risk that the Treeline transaction may not be completed in a timely manner or at all; (vi) the ability to obtain the requisite approval for the sale of the Treeline transaction from stockholders of Standard
        BioTools; (vii) the possibility that competing offers or acquisition proposals will be made with respect to the Treeline business;&#160; (viii) the possibility that any or all of the various conditions to the consummation of the Treeline transaction may
        not be satisfied or waived; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the Treeline transaction, including in circumstances that would require Standard BioTools to pay a termination fee
        or other expenses; (x) the effect of the pendency of the Treeline transaction on the parties&#8217; ability to retain and hire key personnel, their ability to maintain relationships with customers, suppliers and others with whom they do business, their
        business generally or their stock price; (xi) risks related to diverting management&#8217;s attention from ongoing business operations or the loss of one or more members of the management team; (xii) the risk that stockholder litigation in connection
        with either the sale of the Mass Cytometry business or the Treeline transaction may result in significant costs of defense, indemnification and liability; (xiii) the parties&#8217; ability to realize the anticipated benefits of the Treeline transaction;
        (xiv) the risk that the parties may assume unexpected liabilities and expenses as a result of the Treeline transaction; (xv) the risk that the potential disposition of Standard BioTools&#8217; Microfluidics business may not be completed on favorable
        terms or at all; (xvi) the risk that Standard BioTools could fail to maintain the listing of its common stock on Nasdaq; (xvii) uncertainties as to the potential for development, commercialization and other benefits of any of Treeline&#8217;s product
        candidates; and (xviii) uncertainties as to Treeline&#8217;s anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for commencing clinical trials and announcing data and other clinical
        results.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For information regarding other related risks, see the &#8220;Risk Factors&#8221; section of Standard BioTools&#8217; Annual Report on Form 10-K for the year ended December 31, 2025, filed
        with the SEC on March 16, 2026, Standard BioTools&#8217; most recent Quarterly Report on Form 10-Q and Standard BioTools&#8217; other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from
        expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional Information and Where to Find It</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This Current Report on Form 8-K may be deemed to be solicitation material in respect of Standard BioTools&#8217; sale of its Mass Cytometry business and/or in respect of the
        Treeline transaction. In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement on Form S-4 on July 20, 2026 that included
        a preliminary proxy statement and a preliminary prospectus of Standard BioTools, and that may be amended or supplemented from time to time. In connection with the disposition of the Mass Cytometry business and related stockholder vote, Standard
        BioTools will file a preliminary proxy statement with the SEC. This communication is not a substitute for the preliminary proxy statement, preliminary prospectus or any other document that Standard BioTools may file with the SEC or send to its
        stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Any definitive proxy
        statement/prospectus (if and when available) will be mailed to stockholders of Standard BioTools.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY
        REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STANDARD
        BIOTOOLS, TREELINE AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools&#8217; Investor Relations website at https://investors.standardbio.com or
        by contacting Standard BioTools&#8217; Investor Relations department at ir@standardbio.com. In addition, all of those materials will be available at no charge on the SEC&#8217;s website at www.sec.gov.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Participants in the Solicitation</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in
        the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard
        BioTools&#8217; executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools&#8217; proxy statement for its 2026 annual meeting of stockholders (including under the headings &#8220;Management and
        Corporate Governance,&#8221; &#8220;Executive Officer and Director Compensation,&#8221; &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Certain Relationships and Related Transactions,
        and Director Independence&#8221;), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools&#8217; other filings with the SEC. Information regarding Treeline&#8217;s directors and
        executive officers who may be deemed participants in the solicitation is contained in the registration statement on Form S-4 filed by Standard BioTools. These documents are or will be available free of charge at the SEC&#8217;s website at www.sec.gov or
        by going to Standard BioTools&#8217; Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools&#8217; Investor Relations department at ir@standardbio.com.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Exhibit No.</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20078901_ex2-1.htm">2.1</a></div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 88%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Termination, Waiver and Release Agreement, by and among Illumina, Inc. and Standard BioTools Inc. dated as of July 24, 2026.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20078901_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 88%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Press Release, dated as of July 28, 2026.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman';">104</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 88%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned hereunto duly authorized.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Date: July 28, 2026</div>
            </td>

    <td colspan="3" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">STANDARD BIOTOOLS INC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

    <td rowspan="1" colspan="3" style="vertical-align: top; font-size: 10pt;"><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
            </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ Alex Kim</div>
            </td>

    <td style="width: 15%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name: Alex Kim</div>
            </td>

    <td style="width: 15%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

    <td style="width: 45%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title: Chief Financial Officer</div>
            </td>

    <td style="width: 15%; vertical-align: top; font-size: 10pt;"><br/>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div><span style="font-size: 10pt;"><br/>
      </span></div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ef20078901_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-size: 10pt;"><font style="font-weight: bold;">Exhibit 2.1</font><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"><a name="calDraftDate"></a></div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Execution Version</div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">TERMINATION, WAIVER AND RELEASE AGREEMENT</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This TERMINATION, WAIVER AND RELEASE AGREEMENT (this &#8220;<font style="font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;) is made as of July 24,
      2026, by and between Illumina, Inc., a Delaware corporation (&#8220;<font style="font-family: 'Times New Roman';"><u>Purchaser</u></font>&#8221;), and Standard BioTools Inc., a Delaware corporation (&#8220;<font style="font-family: 'Times New Roman';"><u>Seller</u></font>&#8221;
      and, together with Purchaser, the &#8220;<font style="font-family: 'Times New Roman';"><u>Parties</u></font>&#8221; and each a &#8220;<font style="font-family: 'Times New Roman';"><u>Party</u></font>&#8221;).&#160; Capitalized terms used herein and not otherwise defined shall
      have the respective meanings assigned to such terms in the SPA or, if not defined therein, in the 2% Royalty Agreement, the 5% Royalty Agreement or the License Agreement (each as defined below), as applicable.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RECITALS</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Purchaser and Seller entered into that certain Stock Purchase Agreement, dated as of June 22, 2025 (the &#8220;<font style="font-family: 'Times New Roman';"><u>SPA</u></font>&#8221;), pursuant to which, among other things, Purchaser acquired the Shares on the Closing Date;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, pursuant to Section 2.4 of the SPA, Seller is entitled to receive earnout payments from Purchaser to the extent earned in accordance with the
      terms of Exhibit A of the SPA, including an Annual Earnout Payment in respect of the 2026 Earnout Period (the &#8220;<font style="font-family: 'Times New Roman';"><u>2026 Earnout Obligation</u></font>&#8221;);</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, in accordance with Section 2.5 of the SPA, Purchaser and Seller entered into that certain Royalty Agreement, dated as of January 30, 2026,
      providing for the payment by Purchaser to Seller of a royalty equal to two percent (2%) of certain revenues in respect of sales of SOMAmer-based next-generation sequencing library preparation kits during the term thereof (the &#8220;<font style="font-family: 'Times New Roman';"><u>2% Royalty Agreement</u></font>&#8221;);</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, in accordance with Section 2.7 of the SPA, Purchaser and Seller entered into that certain Royalty Agreement, dated as of January 30, 2026,
      providing for the payment by Purchaser to Seller of a royalty equal to five percent (5%) of certain revenues in respect of sales of Single SOMAmers during the term thereof (the &#8220;<font style="font-family: 'Times New Roman';"><u>5% Royalty Agreement</u></font>&#8221;
      and, together with the 2% Royalty Agreement, the &#8220;<font style="font-family: 'Times New Roman';"><u>Royalty Agreements</u></font>&#8221;);</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, under each Royalty Agreement, Purchaser is obligated to pay to Seller certain Royalties that accrue and are calculated and paid on a
      quarterly basis, together with certain other amounts payable thereunder (the &#8220;<font style="font-family: 'Times New Roman';"><u>Royalty Obligations</u></font>&#8221; and, together with the 2026 Earnout Obligation, the &#8220;<font style="font-family: 'Times New Roman';"><u>Contingent Obligations</u></font>&#8221;);</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, in accordance with Section 2.6 of the SPA, Purchaser and Seller entered into that certain License Agreement, dated as of January 30, 2026,
      granting Seller a license under certain intellectual property pertaining to the exploitation of Single SOMAmers and other Licensed Products intended for use in Singleplex Affinity Assays (the &#8220;<font style="font-family: 'Times New Roman';"><u>License
          Agreement</u></font>&#8221;); and</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Parties desire to provide for the full satisfaction and discharge of all Contingent Obligations and to terminate the Royalty Agreements
      and the License Agreement in exchange for a one-time payment by Purchaser to Seller in the amount of $30,041,683.63 (the &#8220;<font style="font-family: 'Times New Roman';"><u>Consideration Payment</u></font>&#8221;).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, in good and valuable consideration of the representations, warranties, covenants and agreements hereinafter set forth, and intending
      to be legally bound hereby, Seller and Purchaser agree as follows:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE I.</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">TERMINATION, WAIVER AND RELEASE</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref233755334"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.01</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Waiver and Release of 2026 Earnout Obligation</u></font>.&#160; Effective upon Seller&#8217;s receipt in full of the Consideration Payment, Seller hereby (a) waives any and all rights or claims of
        Seller arising under Section 2.4 of the SPA or Exhibit A thereto, including any and all rights or claims to any Annual Earnout Payment in respect of the 2026 Earnout Period, and (b) releases Purchaser and its Affiliates from any and all obligations
        arising under Section 2.4 of the SPA or Exhibit A thereto, including the 2026 Earnout Obligation.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref233755762"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.02</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Waiver and Release of Royalty Obligations; Termination of Royalty Agreements</u></font>.&#160; Effective upon Seller&#8217;s receipt in full of the Consideration Payment, (a) Seller hereby waives any
        and all rights or claims of Seller arising under each Royalty Agreement and under Section 2.5 and Section 2.7 of the SPA and (b) Seller hereby releases Purchaser and its Affiliates from any and all obligations arising under each Royalty Agreement
        and Section 2.5 and Section 2.7 of the SPA, including any and all Royalty Obligations. The Parties hereby agree that each Royalty Agreement is terminated and of no further force or effect, effective upon Seller&#8217;s receipt in full of the
        Consideration Payment; <font style="font-family: 'Times New Roman';"><u>provided</u></font> that, notwithstanding anything to the contrary in this <font style="font-family: 'Times New Roman';"><u>Section 1.02</u></font>, the confidentiality
        obligations set forth in Section 4.06 of each Royalty Agreement and, solely to the extent applicable to such confidentiality obligations, Section 4.01 of each Royalty Agreement, shall survive and remain in full force and effect in accordance with
        their terms.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref234339422"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.03</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Waiver and Release of License Agreement Obligations; Termination of License Agreement</u></font>.&#160; Effective upon Seller&#8217;s receipt in full of the Consideration Payment, (a) each Party hereby
        waives any and all rights or claims of such Party arising under the License Agreement and under Section 2.6 of the SPA, (b) each Party hereby releases the other Party and its Affiliates from any and all obligations arising under the License
        Agreement and Section 2.6 of the SPA and (c) Seller hereby covenants and agrees to promptly undertake each of the actions set forth in Sections 8.5(a)(i)-(iii) of the License Agreement. The Parties hereby agree that the License Agreement is
        terminated and of no further force or effect, effective upon Seller&#8217;s receipt in full of the Consideration Payment, except as expressly provided in Section 8.5(b) of the License Agreement.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref235034667"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.04</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Waiver of Unknown Claims</u></font>.&#160; With respect to the rights, claims and obligations waived or released pursuant to <font style="font-family: 'Times New Roman';"><u>Section 1.01</u></font>,
        <font style="font-family: 'Times New Roman';"><u>Section 1.02</u></font> and <font style="font-family: 'Times New Roman';"><u>Section 1.03</u></font> of this Agreement, each Party hereby expressly waives any and all rights conferred upon such
        Party by any statute or rule of law which provides that a release does not extend to claims which the claimant does not know or suspect to exist in its favor at the time of executing the release, which if known by it would have materially affected
        its settlement with the released party, including, without limitation, the following provisions of California Civil Code Section 1542: &#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO
        EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#8221;&#160; Each Party being aware of said code section and any similar,
        applicable state law, agrees to expressly waive any rights that such Party may have thereunder, as well as under any other statute or common law principles of similar effect with respect to the rights, claims and obligations waived or released
        pursuant to <font style="font-family: 'Times New Roman';"><u>Section 1.01</u></font>, <font style="font-family: 'Times New Roman';"><u>Section 1.02</u></font> and <font style="font-family: 'Times New Roman';"><u>Section 1.03</u></font> of this
        Agreement.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.05</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Consideration Payment</u></font>. <a name="z_Ref487458812"></a> As consideration for the foregoing, on the date hereof and promptly following the execution of this Agreement,
          Purchaser shall pay, or cause to be paid, to Seller the Consideration Payment by wire transfer of immediately available funds to an account designated in writing by Seller.&#160; The Parties acknowledge and agree that the Consideration Payment
          constitutes the sole and complete consideration for the termination of the Royalty Agreements, the License Agreement and Seller&#8217;s waivers and releases set forth in <font style="font-family: 'Times New Roman';"><u>Section 1.01</u></font>, <font style="font-family: 'Times New Roman';"><u>Section 1.02</u></font>, <font style="font-family: 'Times New Roman';"><u>Section 1.03</u></font> and <font style="font-family: 'Times New Roman';"><u>Section 1.04</u></font>.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.06</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Satisfaction and Discharge of Contingent Obligations</u></font>.&#160; The Parties acknowledge and agree that the payment of the Consideration Payment shall constitute the full
          satisfaction and discharge of all Contingent Obligations and other obligations, whether known or unknown, under the Royalty Agreements.&#160; Notwithstanding anything to the contrary in the SPA, either Royalty Agreement or the License Agreement,
          effective upon Seller&#8217;s receipt in full of the Consideration Payment, Purchaser shall have no further obligation to pay, and Seller shall have no further right to receive, any amount in respect of any Contingent Obligation or other obligation,
          whether known or unknown, under the Royalty Agreements, whether arising before or after the execution of this Agreement.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.07</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Effect on the SPA</u></font>.&#160; Except as expressly waived or released pursuant to this Agreement, the SPA shall remain in full force and effect in accordance with its terms.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE II.</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">REPRESENTATIONS AND WARRANTIES</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 2.01</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Mutual Representations and Warranties</u></font>.&#160; Each Party represents and warrants to the other Party, as of the date of this Agreement, as follows:</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Organization</u></font>.&#160; Such Party is duly organized, validly existing and in good standing under the Laws of the State of Delaware.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Authority</u></font>.&#160; Such Party has all necessary corporate power and authority to execute and deliver this Agreement and to perform
          its obligations hereunder.&#160; The execution and delivery of and performance by such Party of this Agreement has been duly authorized and approved by all requisite corporate action by such Party.&#160; This Agreement has been duly executed and delivered
          by such Party and, assuming due authorization, execution and delivery hereof by the other Party, constitutes a legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref233755189"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Noncontravention</u></font>.&#160; Neither the execution and delivery of this Agreement by such Party, nor the consummation by such Party of the transactions
        contemplated by this Agreement, shall (i) conflict with or violate any provision of the certificate of incorporation and bylaws of such Party, (ii) violate any Law or Order applicable to such Party or its Subsidiaries or (iii) result in any breach
        of, or constitute a default (with or without notice or lapse of time, or both) under, or give rise to any right of termination, amendment, acceleration or cancellation of, or result in any material or increased, additional, accelerated or
        guaranteed rights or entitlements of any Person under, any Contract to which such Party or any of its Subsidiaries is a party, except, in the case of clauses (ii) or (iii) of this <font style="font-family: 'Times New Roman';"><u>Section 2.01(c)</u></font>,
        as would not, individually or in the aggregate, reasonably be expected to delay or impair the ability for such Party to consummate the transactions contemplated by this Agreement.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 2.02</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Seller Representations and Warranties</u></font>. Seller represents and warrants to Purchaser that (a) Seller has obtained the prior written consent of Treeline Biosciences, Inc. (&#8220;<font style="font-family: 'Times New Roman';"><u>Treeline</u></font>&#8221;) to Seller&#8217;s execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement, in each case to the extent such consent
          is required under that certain Agreement and Plan of Merger and Reorganization, dated as of June 6, 2026, by and among Treeline, Seller and Siri Merger Sub, Inc., and (b) Seller has not granted a security or other interest in, or assigned its
          right to receive, any or all unpaid Royalties under either Royalty Agreement to any Person.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE III.</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">MISCELLANEOUS</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 3.01</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Entire Agreement</u></font>.&#160; The SPA, the Royalty Agreements, the License Agreement and this Agreement constitute the entire agreement between the Parties with respect to the
          matters covered hereby and supersede all previous written, oral or implied understandings between them with respect to such matters.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 3.02</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Fees and Expenses</u></font>.&#160; All fees and expenses incurred in connection with this Agreement shall be paid by the Party incurring such fees or expenses.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 3.03</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Incorporation by Reference</u></font>.&#160; Each of Section 11.6 (Counterparts; Electronic Signatures), Section 11.8 (Governing Law; Jurisdiction), Section 11.9 (Specific Enforcement),
          Section 11.10 (WAIVER OF JURY TRIAL), Section 11.11 (Notices), Section 11.12 (Severability), Section 11.14 (Interpretation) and Section 11.15 (No Recourse) of the SPA is incorporated herein by reference, <font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[<font style="font-family: 'Times New Roman'; font-style: italic;">Signature Page Follows</font>]</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the date first written above.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <table cellspacing="0" cellpadding="0" border="0" id="zc275df1f3526468785042dd404025919" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;"><a name="z_DV_M327"></a>STANDARD BIOTOOLS INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1" rowspan="1">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;">
            <div style="text-align: left; font-family: 'Times New Roman'; margin-left: 18pt;">By:</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" colspan="1"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
          </td>
          <td style="width: 1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="width: 36%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">/s/ Michael Egholm</div>
          </td>
          <td style="width: 8%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 1%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Michael Egholm</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="width: 1%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: President and Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zaf45c3f56daa43ab91829845e54b7a77" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">ILLUMINA, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;" colspan="1" rowspan="1">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 50%;">
            <div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman';">By:</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" colspan="1"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; width: 1%;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; width: 36%;">
            <div style="text-align: left; font-family: 'Times New Roman';">/s/ Jacob Thaysen</div>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 8%; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 1%;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Jacob Thaysen</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1"><br>
          </td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 1%;" colspan="1"><br>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[<font style="font-family: 'Times New Roman'; font-style: italic;">Signature Page to Termination, Waiver and Release Agreement</font>]</div>
    <div style="font-size: 10pt;">&#160;<br>
      <br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ef20078901_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"> <font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Standard BioTools Announces Sale of Mass Cytometry Business and Illumina&#8217;s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team
        and Continued Investment in Next Generation Multiplex Platforms</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina&#8217;s Acquisition of SomaLogic
        Business</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Boston, Mass., July 28, 2026</font> - Standard BioTools Inc. (NASDAQ: LAB) (&#8220;Standard
        BioTools&#8221; or the &#8220;Company&#8221;) today announced the following updates in connection with the Company&#8217;s previously announced merger with Treeline Biosciences, Inc. (&#8220;Treeline&#8221;):</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za3da4812a9744ea7a8da2122083cb337" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Agreement to sell its Mass Cytometry business to Multiplex Bio, an entity founded and led by advanced imaging industry veterans, Michael Johnson, PhD, Tom Villani, PhD and Charles
                Coffman;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z7bc43a003a744e65907a05be41b541de" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Buyout of the 2026 earnout and all future royalty payments for $30 million related to Illumina, Inc.&#8217;s previously completed acquisition of Standard BioTools&#8217; SomaLogic business;
                and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za71ba09e4fd4476880bda4658b53230c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Early termination of the waiting period by the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Treeline merger.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Sale of Mass Cytometry Business to Multiplex Bio</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Multiplex Bio will be focused on the ongoing commercialization of Standard BioTools&#8217; CyTOF and Hyperion product lines and investment in next generation multiplex
        platforms to advance scientific research. Multiplex Bio intends to maintain the full continuity of the business including all customer relationships, the majority of the Company&#8217;s Mass Cytometry team, existing service and maintenance commitments.
        The business will continue to operate under the Standard BioTools name and brand. Dr. Johnson will serve as Chief Executive Officer, Dr. Villani will serve as Chief Technology Officer and Mr. Coffman will serve as Chief Operating Officer of
        Multiplex Bio.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Johnson and Dr. Villani co-founded Visikol, where they pioneered the commercialization of spatial biology tools including 3D microscopy, multiplex tissue imaging and
        digital pathology services for the world&#8217;s leading pharmaceutical companies, building Visikol into a recognized leader in advanced tissue imaging before its acquisition by BICO in 2021. Mr. Coffman&#8217;s operational and financial background spans
        building and scaling life science businesses through periods of transition and growth.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, &#8220;Our Mass Cytometry technology, including the CyTOF and Hyperion instruments,
        provide unmatched multi-plexing capabilities for biomedical researchers studying a wide range of diseases. After a comprehensive evaluation of opportunities for this business, we are confident that Michael, Tom and Charles are uniquely positioned
        to steward our products and team given their scientific depth, commercial, operational experience and passion for the technology. Our products will continue to make a meaningful difference in single cell research and in the evolution of spatial
        biology.&#8221;</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right;">Page 1 of 5</div>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The Standard BioTools Mass Cytometry business has an extraordinary scientific legacy and we are honored to carry it forward,&#8221; said Dr. Johnson. &#8220;CyTOF and Hyperion have
        been foundational to the field of multiplex proteomic detection, and our goal is to build on that foundation and dedicate ourselves fully to advancing these platforms and supporting the scientists who depend on them every day. Our team has operated
        this technology firsthand and we understand deeply what it means to the customers and researchers who rely on it. We are genuinely excited by what lies ahead for this business and the broader field of multiplex proteomic imaging and detection where
        we strongly believe Standard BioTools&#8217;s products and team are positioned to lead the entire field.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The transaction is valued at up to $10 million, comprising a seller&#8217;s note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard
        BioTools has agreed to provide Multiplex Bio with a working capital loan of up to $10 million at the closing of the transaction.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The transaction is expected to close by the end of 2026, substantially concurrently with the closing of the Treeline transaction, subject to approval by Standard
        BioTools&#8217; stockholders and other customary closing conditions.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Illumina Earnout and Royalty Buyout Payment</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Standard BioTools received approximately $30 million as a buyout of the 2026 earnout and all accrued and unpaid royalty payments related to Illumina, Inc.&#8217;s previously
        completed acquisition of Standard BioTools&#8217; SomaLogic business. This payment will now be included in Standard BioTools&#8217; pro forma net cash position at closing of the Treeline transaction, which will be used in determining the value of Standard
        BioTools in the exchange ratio in the Treeline transaction, in each case subject to the terms of the merger agreement with Treeline.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pending Transaction with Treeline</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">On July 20, 2026, Standard BioTools filed its registration statement on Form S-4 with the U.S. Securities and Exchange Commission. On July 21, 2026, the U.S. Federal
        Trade Commission provided early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Company expects the Treeline transaction to close by the end of 2026, subject to approval by Standard BioTools stockholders and other customary closing conditions.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Standard BioTools Inc.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class
        operations and a world class management team. The Company&#8217;s established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com
        or connect with us on X, Facebook&#174;, LinkedIn, and YouTube&#8482;.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For Research Use Only. Not for use in diagnostic procedures.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Limited Use Label License and other terms may apply: <u>standardbio.com/legal/terms-and-conditions/.</u> Patent and License Information: <u>standardbio.com/legal/notices</u>.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Trademarks: <u>standardbio.com/legal/trademarks</u>. Any other trademarks are the sole property of their respective owners. &#169;2026 Standard BioTools Inc.. All rights
        reserved.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right;">Page 2 of 5</div>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements
        regarding the disposition of the Mass Cytometry business; the expected timing of the disposition of the Mass Cytometry business; the Treeline transaction; the expected timing of the closing of the Treeline transaction; the potential benefits of the
        Treeline transaction; the prospective performance and outlook of the combined company&#8217;s business, performance and opportunities&#894; as well as any assumptions underlying any of the foregoing. The words &#8220;advance,&#8221; &#8220;build,&#8221; &#8220;lead,&#8221; &#8220;may,&#8221; &#8220;will,&#8221;
        &#8220;continue,&#8221; &#8220;commitment,&#8221; &#8220;expect,&#8221; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially
        different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the risk that the sale of the Mass Cytometry
        business may not be completed in a timely manner or at all; (ii) the ability to obtain the requisite approval for the sale of the Mass Cytometry business from stockholders of Standard BioTools; (iii) the possibility that any or all of the various
        conditions to the consummation of the sale of the Mass Cytometry business may not be satisfied or waived; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement relating to the sale
        of the Mass Cytometry business; (v) the risk that the Treeline transaction may not be completed in a timely manner or at all; (vi) the ability to obtain the requisite approval for the sale of the Treeline transaction from stockholders of Standard
        BioTools; (vii) the possibility that competing offers or acquisition proposals will be made with respect to the Treeline business;&#160; (viii) the possibility that any or all of the various conditions to the consummation of the Treeline transaction may
        not be satisfied or waived; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the Treeline transaction, including in circumstances that would require Standard BioTools to pay a termination fee
        or other expenses; (x) the effect of the pendency of the Treeline transaction on the parties&#8217; ability to retain and hire key personnel, their ability to maintain relationships with customers, suppliers and others with whom they do business, their
        business generally or their stock price; (xi) risks related to diverting management&#8217;s attention from ongoing business operations or the loss of one or more members of the management team; (xii) the risk that stockholder litigation in connection
        with either the sale of the Mass Cytometry business or the Treeline transaction may result in significant costs of defense, indemnification and liability; (xiii) the parties&#8217; ability to realize the anticipated benefits of the Treeline transaction;
        (xiv) the risk that the parties may assume unexpected liabilities and expenses as a result of the Treeline transaction; (xv) the risk that the potential disposition of Standard BioTools&#8217; Microfluidics business may not be completed on favorable
        terms or at all; (xvi) the risk that Standard BioTools could fail to maintain the listing of its common stock on Nasdaq; (xvii) uncertainties as to the potential for development, commercialization and other benefits of any of Treeline&#8217;s product
        candidates; and (xviii) uncertainties as to Treeline&#8217;s anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for commencing clinical trials and announcing data and other clinical
        results.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For information regarding other related risks, see the &#8220;Risk Factors&#8221; section of Standard BioTools&#8217; Annual Report on Form 10-K for the year ended December 31, 2025, filed
        with the SEC on March 16, 2026, Standard BioTools&#8217; most recent Quarterly Report on Form 10-Q and Standard BioTools&#8217; other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from
        expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right;">Page 3 of 5</div>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional Information and Where to Find It</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This communication may be deemed to be solicitation material in respect of Standard BioTools&#8217; sale of its Mass Cytometry business and/or in respect of the Treeline
        transaction. In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement on Form S-4 on July 20, 2026 that included a
        preliminary proxy statement and a preliminary prospectus of Standard BioTools, and that may be amended or supplemented from time to time. In connection with the disposition of the Mass Cytometry business and related stockholder vote, Standard
        BioTools will file a preliminary proxy statement with the SEC. This communication is not a substitute for the preliminary proxy statement, preliminary prospectus or any other document that Standard BioTools may file with the SEC or send to its
        stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Any definitive proxy
        statement/prospectus (if and when available) will be mailed to stockholders of Standard BioTools.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY
        REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STANDARD
        BIOTOOLS, TREELINE AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools&#8217; Investor Relations website at https://investors.standardbio.com or
        by contacting Standard BioTools&#8217; Investor Relations department at ir@standardbio.com. In addition, all of those materials will be available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u>.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Participants in the Solicitation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in
        the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard
        BioTools&#8217; executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools&#8217; proxy statement for its 2026 annual meeting of stockholders (including under the headings &#8220;Management and
        Corporate Governance,&#8221; &#8220;Executive Officer and Director Compensation,&#8221; &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Certain Relationships and Related Transactions,
        and Director Independence&#8221;), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools&#8217; other filings with the SEC. Information regarding Treeline&#8217;s directors and
        executive officers who may be deemed participants in the solicitation is contained in the registration statement on Form S-4 filed by Standard BioTools. These documents are or will be available free of charge at the SEC&#8217;s website at www.sec.gov or
        by going to Standard BioTools&#8217; Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools&#8217; Investor Relations department at ir@standardbio.com.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right;">Page 4 of 5</div>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contacts</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Investors:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>ir@standardbio.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Media:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dan Moore / Nick Lamplough / Tali Epstein</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Collected Strategies</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>LAB-CS@collectedstrategies.com</u></div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
  </div>
  <div style="width: 100%;" class="BRPFPageFooter">
    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right;">Page 5 of 5</div>
    <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>lab-20260724.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<xs:schema targetNamespace="http://standardbio.com/20260724" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:lab="http://standardbio.com/20260724" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="lab-20260724_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="lab-20260724_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://standardbio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lab-20260724_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lab-20260724_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://standardbio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="lab-20260724.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://standardbio.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 24, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 24,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Standard BioTools Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001162194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0513190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">50 Milk Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">10th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-6000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LAB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20078901_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://standardbio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20078901_8k.htm">ef20078901_8k.htm</File>
    <File>lab-20260724.xsd</File>
    <File>lab-20260724_lab.xml</File>
    <File>lab-20260724_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20078901_8k.htm": {
   "nsprefix": "lab",
   "nsuri": "http://standardbio.com/20260724",
   "dts": {
    "inline": {
     "local": [
      "ef20078901_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "lab-20260724.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lab-20260724_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lab-20260724_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://standardbio.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20260724to20260724",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20078901_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260724to20260724",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20078901_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://standardbio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-26-029841-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-26-029841-xbrl.zip
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MMW17^3,-IE?15#U1UVJ0@P(>%-(TE@X,@C\ ;I$\(]D#=6=]QE!,')(@"K*
MAF^%",.V[](%C0J\;?#NWA%Y=X -5,?J+2%59HEZT8D3&%ZR(!%7=2?.LG@.
M72WN21J'@4><$#A=/\_BQ2&QUQ\J4 & ^UQ42'GP@*@HR!F0NQE+WI(Y36Z"
MJ(YBYY#091;K6XD8A=]#8<<GI*<F?JO9E?7\)6+01C'(;]S)R3EQZ %V/UV,
MKT<G9'H]O!Y-<Q1K6"H7QZY8G&\&^71T_&DROAZ/IF1X<4)&?QS_.KSX."+'
ME^?GX^ET?'GQ?$"UJH#Z?3C]=7SQ\?KRHD9.&L<-T(<=>_!\@#2K "'OG.1
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MP $$_;C(\Q"W(-:*!JY>&E[:BNI*!:'6QJ\A0=XQ-+'34EC7.URPB),J5J,
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M^!\ -_8''I*>>%C$PX>UNE,=UH]<SFM5/GA5/JF\.JG51;TV..;'Q\_/U7B
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MBUS%(M<+=H8B+. 2W,FZ453$,N%__N'MP?Z;TPQ^7:@BQ]O.83F0=13^6[Y
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M@,/]EB\[)8E&VF$XT(7',):H.<2Z,A^.W$R\:*@D&F_(8$?X.9)C:TJ"2KN
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MBA?H#FVZ/3:F>*VWOH+2O@#8$,U_3-WO4O( $MPOZ?%Y$_\0:1MH6YO-%S^
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MN_J7/ .*+5J)2ZW6&=*64;@3JP]@QE?73[#,[$@6](CLMMJ29Y0 8E[315X
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MRW+%<,&!5>2*;]#FPIL2YPE.U&R"Z@OJJ*95$Z<TUN9*Q8F0LKHB!9^KDJ/
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M   1              "  0    !E9C(P,#<X.3 Q7SAK+FAT;5!+ 0(4 Q0
M   ( )%B_%P/DJMLAQ8   2'   4              "  4<F  !E9C(P,#<X
M.3 Q7V5X,BTQ+FAT;5!+ 0(4 Q0    ( )%B_%P<I83]2!D  %)I   5
M          "  0 ]  !E9C(P,#<X.3 Q7V5X.3DM,2YH=&U02P$"% ,4
M" "18OQ<C&L8!T4#   _#P  $               @ %[5@  ;&%B+3(P,C8P
M-S(T+GAS9%!+ 0(4 Q0    ( )%B_%RW1O-,>@@  #!6   4
M  "  >Y9  !L86(M,C R-C W,C1?;&%B+GAM;%!+ 0(4 Q0    ( )%B_%Q7
MAO[$W@4  /8^   4              "  9IB  !L86(M,C R-C W,C1?<')E
:+GAM;%!+!08     !@ & (8!  "J:      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ef20078901_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lab-20260724.xsd" xlink:type="simple"/>
    <context id="c20260724to20260724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20260724to20260724"
      id="Fact_861ec0aef1d84f5ba7c6c697e0ef6b68">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20260724to20260724"
      id="Fact_176632a8287a461e813df44714114ebe">0001162194</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20260724to20260724"
      id="Fact_ee836757957043af84fe802cb3246a11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20260724to20260724"
      id="Fact_f9821ea81345473e929c41317545c072">2026-07-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20260724to20260724"
      id="Fact_a23463cd153545f8a9ba78d5839e701f">Standard BioTools Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20260724to20260724"
      id="Fact_2682c261781c404b8aeafa6dfeaf8286">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20260724to20260724"
      id="Fact_4ed55bcd72a34823868315fdbc8cdb4c">001-34180</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20260724to20260724"
      id="Fact_c1dfbe6c65be4b67b6dbb34b6907dfb7">77-0513190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20260724to20260724"
      id="Fact_9bc1eab1ad834bf0af813a4f4ac9273c">50 Milk Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20260724to20260724"
      id="Fact_6ba03140fac54ffe93bfb829328e54e4">10th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20260724to20260724"
      id="Fact_d28c2f40cb624077b7b54f0f2ab27cbd">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20260724to20260724"
      id="Fact_b397fe831fae48b2914ce97992ee4bbb">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20260724to20260724"
      id="Fact_d6be81257b2d445aa71db67f9856f0c3">02109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20260724to20260724"
      id="Fact_cc7ae89db63d4e85b67baeb7cb4dd950">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20260724to20260724"
      id="Fact_63c465d4a012458196326116d406dad9">266-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20260724to20260724"
      id="Fact_98ee54a9da5543dda089b25dd5261292">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20260724to20260724"
      id="Fact_9d1ad37624e446ae84145258f187e7f5">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20260724to20260724"
      id="Fact_e6b5c3a5ca634811b3b6808a5c397b27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20260724to20260724"
      id="Fact_593185b7f7e7427ca3fb46c7749e8540">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20260724to20260724"
      id="Fact_f1f4ee78351a4f1b93aae1ab15595f01">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20260724to20260724"
      id="Fact_42b45e70351444d989005ffa573a643d">LAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20260724to20260724"
      id="Fact_6a609d36738e4ec6861e49adb760ed04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20260724to20260724"
      id="Fact_1a9a2b7eef0d44a3b18f77481bee5c6d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
